Business Akumentis Healthcare Reports ₹446 Crore Revenue, ₹77 Crore Profit in FY26 Adarsh SinghJuly 23, 2026050 views How Did Akumentis Healthcare Maintain Profitability Amid Modest Revenue Growth in FY26? Akumentis Healthcare, a Thane based pharmaceutical company, reported steady financial performance in FY26, posting ₹446 crore in operating revenue and ₹77 crore in net profit. While revenue growth remained modest over the past two financial years, the company continued to strengthen its profitability through disciplined cost management and a diversified portfolio of prescription medicines. According to the company’s standalone financial statements filed with the Registrar of Companies (RoC), operating revenue increased to ₹446 crore in FY26, up from ₹434 crore in FY25. Compared to FY24, when the company generated ₹398 crore, Akumentis has recorded gradual but consistent topline growth over the last two years. The company operates in India’s branded prescription drug market and continues to focus on expanding its presence across multiple therapeutic segments. Prescription Medicines Remain the Sole Revenue Driver Akumentis Healthcare derives its entire operating revenue from the sale of pharmaceutical products. The company currently markets more than 167 branded prescription products across a wide range of therapeutic categories, including: Gynecology Cardiology Orthopedics Pediatrics Dermatology Its diversified product portfolio enables the company to cater to multiple specialty healthcare segments, reducing dependence on any single therapy area. Apart from operating revenue, Akumentis also generated ₹17.3 crore in other income, primarily from interest earned on deposits. This lifted the company’s total income to ₹464 crore in FY26, compared to ₹449 crore in the previous financial year. RBI Says Indian Economy Remains Resilient Despite West Asia Conflict READ MORE Operating Costs Decline Marginally Despite higher revenue, Akumentis managed to keep its operating expenses under control. The company’s total expenditure declined slightly to ₹360 crore in FY26, from ₹362 crore in FY25, reflecting improved operational efficiency. The major expense heads included: Employee benefits: ₹130 crore Cost of materials consumed: ₹115 crore Advertising and promotional expenses: ₹37 crore Travelling expenses: ₹28 crore Legal and professional fees: ₹23 crore Employee costs remained the company’s largest expense, although they declined compared to the previous year. Lower overall expenditure helped improve profitability despite only moderate revenue growth. Profit Rises to ₹77 Crore Akumentis Healthcare reported a net profit of ₹77 crore in FY26, compared to ₹66 crore in FY25, representing healthy year-on-year growth. The reported profit reflects the company’s underlying operating performance after excluding an exceptional impairment expense of ₹63 crore related to loans. By adjusting for this one-time item, the financial results present a clearer picture of the company’s core business performance. The company also delivered strong profitability metrics during the year, including: EBITDA Margin: 20.14% Return on Capital Employed (ROCE): 39.21% These figures indicate efficient capital utilisation and healthy operating margins despite a competitive pharmaceutical market. Strong Cash Position Supports Financial Stability Akumentis continued to maintain a healthy balance sheet during FY26. As of March 2026, the company reported: Current assets: ₹271 crore Cash and bank balances: ₹199 crore The company’s efficient cost structure is reflected in its unit economics as well. According to the financial statements, Akumentis spent ₹0.81 to earn every ₹1 of operating revenue, highlighting its operational efficiency. A strong cash position provides the company with flexibility to invest in future growth, product expansion, and business development. Funding and Recent Tax Notice Akumentis Healthcare has raised approximately $19 million in funding to date, with Peak XV Partners being its largest external investor. Recently, parent company AKUM Drugs, along with its subsidiary Akumentis Healthcare, received an income tax demand notice of ₹134 crore. The company has not indicated any impact of the notice on its FY26 financial performance. What’s Next for Akumentis Healthcare? Akumentis Healthcare’s FY26 performance reflects a business focused on sustainable growth rather than aggressive expansion. While revenue growth remained moderate, improved cost control and strong operating margins helped the company deliver higher profitability. With a diversified portfolio of over 167 branded prescription medicines, healthy cash reserves, and robust return ratios, Akumentis appears well-positioned to strengthen its presence in India’s pharmaceutical market. Going forward, investors and industry observers will closely watch how the company addresses the recent tax demand while continuing to expand its product portfolio and maintain profitable growth.